Literature DB >> 26545325

Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling--A case study with carbaryl.

Kathleen Brown1, Martin Phillips2, Christopher Grulke3, Miyoung Yoon4, Bruce Young5, Robin McDougall6, Jeremy Leonard7, Jingtao Lu7, William Lefew8, Yu-Mei Tan9.   

Abstract

Sources of uncertainty involved in exposure reconstruction for short half-life chemicals were characterized using computational models that link external exposures to biomarkers. Using carbaryl as an example, an exposure model, the Cumulative and Aggregate Risk Evaluation System (CARES), was used to generate time-concentration profiles for 500 virtual individuals exposed to carbaryl. These exposure profiles were used as inputs into a physiologically based pharmacokinetic (PBPK) model to predict urinary biomarker concentrations. These matching dietary intake levels and biomarker concentrations were used to (1) compare three reverse dosimetry approaches based on their ability to predict the central tendency of the intake dose distribution; and (2) identify parameters necessary for a more accurate exposure reconstruction. This study illustrates the trade-offs between using non-iterative reverse dosimetry methods that are fast, less precise and iterative methods that are slow, more precise. This study also intimates the necessity of including urine flow rate and elapsed time between last dose and urine sampling as part of the biomarker sampling collection for better interpretation of urinary biomarker data of short biological half-life chemicals. Resolution of these critical data gaps can allow exposure reconstruction methods to better predict population-level intake doses from large biomonitoring studies. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarker interpretation; CARES; Carbaryl; Discretized Bayesian; Exposure conversion factor; Exposure reconstruction; Markov Chain Monte Carlo; Pharmacokinetic modeling; Physiologically based pharmacokinetic model; Population-based biomonitoring

Mesh:

Substances:

Year:  2015        PMID: 26545325     DOI: 10.1016/j.yrtph.2015.10.031

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Estimating Methylmercury Intake for the General Population of South Korea Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Seungho Lee; Yu-Mei Tan; Martin B Phillips; Jon R Sobus; Sungkyoon Kim
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

Review 2.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Authors:  Yu-Mei Tan; Rachel R Worley; Jeremy A Leonard; Jeffrey W Fisher
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

Review 3.  PBPK model reporting template for chemical risk assessment applications.

Authors:  Yu-Mei Tan; Melissa Chan; Amechi Chukwudebe; Jeanne Domoradzki; Jeffrey Fisher; C Eric Hack; Paul Hinderliter; Kota Hirasawa; Jeremy Leonard; Annie Lumen; Alicia Paini; Hua Qian; Patricia Ruiz; John Wambaugh; Fagen Zhang; Michelle Embry
Journal:  Regul Toxicol Pharmacol       Date:  2020-06-02       Impact factor: 3.271

4.  A Physiologically-Based Pharmacokinetic Modeling Approach Using Biomonitoring Data in Order to Assess the Contribution of Drinking Water for the Achievement of an Optimal Fluoride Dose for Dental Health in Children.

Authors:  Keven J Jean; Nancy Wassef; Fabien Gagnon; Mathieu Valcke
Journal:  Int J Environ Res Public Health       Date:  2018-06-28       Impact factor: 3.390

Review 5.  Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments.

Authors:  Elaine A Cohen Hubal; Barbara A Wetmore; John F Wambaugh; Hisham El-Masri; Jon R Sobus; Tina Bahadori
Journal:  J Expo Sci Environ Epidemiol       Date:  2018-08-16       Impact factor: 5.563

6.  Source reconstruction of airborne toxics based on acute health effects information.

Authors:  Christos D Argyropoulos; Samar Elkhalifa; Eleni Fthenou; George C Efthimiou; Spyros Andronopoulos; Alexandros Venetsanos; Ivan V Kovalets; Konstantinos E Kakosimos
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.